These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23427107)

  • 1. Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.
    Heresco-Levy U; Shoham S; Javitt DC
    Mov Disord; 2013 Apr; 28(4):419-24. PubMed ID: 23427107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.
    Labrie V; Roder JC
    Neurosci Biobehav Rev; 2010 Mar; 34(3):351-72. PubMed ID: 19695284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings.
    Levin R; Dor-Abarbanel AE; Edelman S; Durrant AR; Hashimoto K; Javitt DC; Heresco-Levy U
    J Psychiatr Res; 2015 Feb; 61():188-95. PubMed ID: 25554623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NMDA receptor complex: a long and winding road to therapeutics.
    Wood PL
    IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate as a therapeutic target in psychiatric disorders.
    Javitt DC
    Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
    Fiorentini C; Rizzetti MC; Busi C; Bontempi S; Collo G; Spano P; Missale C
    Mol Pharmacol; 2006 Mar; 69(3):805-12. PubMed ID: 16365282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
    Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A
    Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of a novel pharmacotherapy targeted at the N-methyl-D-aspartate receptor-D-serine system for schizophrenia].
    Nishikawa T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):201-6. PubMed ID: 21226316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained saturating level of glycine induces changes in NR2B-containing-NMDA receptor localization in the CA1 region of the hippocampus.
    Imamura Y; Ma CL; Pabba M; Bergeron R
    J Neurochem; 2008 Jun; 105(6):2454-65. PubMed ID: 18331477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors.
    Mony L; Krzaczkowski L; Leonetti M; Le Goff A; Alarcon K; Neyton J; Bertrand HO; Acher F; Paoletti P
    Mol Pharmacol; 2009 Jan; 75(1):60-74. PubMed ID: 18923063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficit of NMDA receptor activation in CA1 hippocampal area of aged rats is rescued by D-cycloserine.
    Billard JM; Rouaud E
    Eur J Neurosci; 2007 Apr; 25(8):2260-8. PubMed ID: 17445224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
    Javitt DC
    Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamate-based therapeutic approaches: inhibitors of glycine transport.
    Lechner SM
    Curr Opin Pharmacol; 2006 Feb; 6(1):75-81. PubMed ID: 16376148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related effects of the neuromodulator D-serine on neurotransmission and synaptic potentiation in the CA1 hippocampal area of the rat.
    Junjaud G; Rouaud E; Turpin F; Mothet JP; Billard JM
    J Neurochem; 2006 Aug; 98(4):1159-66. PubMed ID: 16790028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G; Lane HY; Yang P; Chong MY; Lange N
    Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
    Yang CR; Svensson KA
    Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant mice with reduced NMDA-NR1 glycine affinity or lack of D-amino acid oxidase function exhibit altered anxiety-like behaviors.
    Labrie V; Clapcote SJ; Roder JC
    Pharmacol Biochem Behav; 2009 Feb; 91(4):610-20. PubMed ID: 18940194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat.
    Gozzi A; Herdon H; Schwarz A; Bertani S; Crestan V; Turrini G; Bifone A
    Psychopharmacology (Berl); 2008 Dec; 201(2):273-84. PubMed ID: 18704372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis.
    Gilmour G; Dix S; Fellini L; Gastambide F; Plath N; Steckler T; Talpos J; Tricklebank M
    Neuropharmacology; 2012 Mar; 62(3):1401-12. PubMed ID: 21420987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.